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DNAzymes (Dzs) are single-stranded DNA catalysts that specifically cleave the mRNA of targeted genes. Compared with other 
gene-silencing technologies, such as ribozymes, antisense oligonucleotide and small interference RNA (siRNA), DNAzymes have 
several advantages, including small molecular weight, diversity, low cost and relative stability in serum. With the evolution of 
molecular technology, the first DNAzyme was generated in vitro in 1994. From then on, DNAzymes have been studied in order to 
understand their structures, chemistry and biological applications. Particularly, DNAzymes have been widely applied as a new 
interference strategy in the treatment of many conditions, including cancer, viral diseases, and cardiovascular diseases. This re-
view mainly summarizes the use of DNAzymes in the areas of cancer research and therapy. 
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The first DNAzyme was produced experimentally in 1994 
by Breaker and Joyce [1], who used in vitro selection to iden-
tify a special DNA sequence that catalyzes Pb2+-dependent 
cleavage of an RNA phosphodiester linkage. Afterwards, a 
number of DNAzymes were created with the capacity to 
catalyze many reactions, including the cleavage of DNA or 
RNA, the modification and ligation of DNA, and the meta-
lation of porphyrin rings. The catalytic properties of 
DNAzymes have been utilized in therapeutic and biosensor 
applications. 
The most commonly studied RNA-cleaving DNAzymes 
are 10–23 (Figure 1(a)) and 8–17 (Figure 1(b)), which both 
require metal ions such as Mg2+ for their activity [2]. The 
8–17 DNAzyme appears to be the simplest DNA motif ca-
pable of RNA cleavage while the 10–23 DNAzyme is the 
best understood model. Each 10–23 DNAzyme has a cata-
lytic domain of 15 deoxyribonucleotides flanked by 2 arms, 
each composed of a substrate-recognition domain of 7–9 
deoxyribonucleotides. This DNAzyme effectively cleaves 
the substrate RNA at unpaired purine: paired pyrimidine 
junctions under physiological conditions [3]. Additional 
RNA-cleaving DNAzymes have also been identified: some 
DNAzymes do not need a divalent metal ion cofactor (Fig-
ure 1(c)) and others that require the amino acid histidine as 
an obligatory cofactor (Figure 1(d)) [2]. 
DNAzymes have the advantages of small molecular  
 
Figure 1  The structure of DNAzymes. Black lines denote RNA; gray 
lines denote DNAzyme. r and R, purine; Y, pyrimidine. 
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weight, low cost and relative serum stability. However, 
there are also some disadvantages such as off-target effects. 
For example, Dz13, a DNAzyme that cleaves c-Jun mRNA, 
is effective against tumors directly, and it also induces a 
cytotoxic stress response. This off-target effect may be in-
duced by up-regulation of the tumor suppressor E2F1, 
which occurs regardless of cellular p53 status [4]. Table 1 
provides a summary of the advantages and disadvantages of 
DNAzymes and three other common gene intervention 
techniques. 
1  Applications of DNAzymes in cancer studies 
The DNAzymes widely used in cancer research are shown 
in Table 2. Yang et al. [7] suggested that a LMP1-specific 
DNAzyme down-regulates the expression of the EBV on-
coprotein LMP1 and inhibits the cellular signaling pathways 
activated by LMP1. This group used a cationic porphyrin 
TMP as a transfection reagent. To increase stability of the 
DNAzyme in cells, two phosphorothioate (PS) linkages 
were introduced to both ends of the arms [7,8]. When an 
egr-1-targeted DNAzyme, another DNAzyme used in can-
cer research, was synthesized with an inverted thymidine 
(Ti) at the 3′ position, the DNAzyme could provide efficient 
resistance to nucleolytic degradation [9]. 
1.1  DNAzymes inhibit cell proliferation 
The bcr-abl oncogene, also known as the Philadelphia 
chromosome (Ph), is detected in >95% of patients with 
chronic myelogenous leukemia (CML) and in 20%–30% of 
adults with acute lymphoblastic leukemia (ALL). The BCR- 
ABL fusion proteins, encoded by the bcr-abl oncogene, 
inhibit apoptosis and induce the accumulation of myeloid 
cells. Among these fusion proteins, p210bcr-abl and p190bcr-abl 
both have increased tyrosine kinase enzymatic activity. The 
over-expression of the kinase is thought to confer a growth 
advantage to Ph+ CML or ALL cells and to play a momen-
tous role in the pathogenesis of the malignancies. An ele-
gant study demonstrated that the DNAzymes targeting 
bcr-abl efficiently cleave only their respective bcr-abl sub-
strates, which led to down-regulation of p210bcr-abl protein 
expression and significant inhibition of the proliferation of 
Ph+ malignant cells. These bcr-abl-specific DNAzymes may 
improve the success rate of autologous stem cell transplants 
by purging the leukemia stem cell populations from patients 
with Ph+ leukemia [19]. 
PML/RARα fusion transcripts are detected in all patients 
with the t (15:17) translocation, which fuses the retinoic 
acid receptor  (RAR) gene on chromosome 17 to the 
promyelocytic leukaemia (PML) gene on chromosome 15 to 
produce the PML/RARα gene. These transcripts are critical  
Table 1  Advantages and disadvantages of DNAzymes compared with ribozymes, antisense oligonucleotide (ASO) and small interference RNA (siRNA) 
Gene intervention techniques Advantages Disadvantages References 
DNAzymes More stable; easier to synthesize; less expensive Off-target effects [2,4] 
Ribozymes Present in nature Less stable; toxic  [5] 
ASO Not dependent on cofactor Less sensible; less selective [5] 
siRNA More active; not dependent on mRNA sequences Dependent on cellular mechanisms; less specific; immune 
response and off-target effects 
[6] 
Table 2  Applications of DNAzymes in cancer research 
Cancer Target Biological effects (in vitro and in vivo) References 
Nasopharyngeal carcinoma LMP1 Inhibiting proliferation and metastasis; promoting apoptosis; enhancing radiosensitivity [7,8] 
Breast cancer egr-1 Inhibiting proliferation and metastasis; suppressing tumor growth [9] 
Lung cancer MMPs Inhibiting invasion and metastasis [10,11] 
Hepatocarcinoma IGF-II Inhibiting adhesion, invasion and metastasis [12] 
Pancreatic carcinoma Survivin Inhibiting proliferation; promoting apoptosis [13] 
Colorectal cancer 1-integrin Inhibiting adhesion and invasion [14] 
 -catenin Inhibiting proliferation [15] 
 k-ras Enhancing radiosensitivity [16] 
Prostatic cancer Aurora kinase A Inhibiting proliferation and metastasis; promoting apoptosis; down-regulating telomerase activity  [17] 
Epithelioma c-Jun Inhibiting proliferation; blocking angiogenesis; suppressing tumor growth [18] 
Leukocythemia Bcr-abl Inhibiting proliferation; enhancing success rate of autologous stem cell transplants [19] 
 PML/RARα Inhibiting proliferation and vitality; promoting apoptosis [20] 
Liposarcoma c-Jun Promoting apoptosis; suppressing tumor growth [21] 
Osteosarcoma uPAR Inhibiting invasion [22] 
 Ezrin Inhibiting proliferation [23] 
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in the development of acute promyelocytic leukemia (APL). 
DNAzymes that cleave the PML/RAR transcripts were 
designed by Kabuli et al. [20]. This research indicated that 
these DNAzymes cleave PML/RAR efficiently and spe-
cifically at the level of mRNA and protein. Moreover, these 
DNAzymes not only show a statistically significant suppres-
sion of cell proliferation and viability, but also promote 
apoptosis of the cells. These biological effects of DNAzymes 
can be enhanced when combined with all-trans-retinoic acid 
(ATRA) [20]. 
1.2  DNAzymes promote cell apoptosis 
Defective apoptosis has been shown to play a critical role in 
tumorigenesis. Apoptosis is mediated by caspases and two 
main apoptosis regulator families: the Bcl-2 family and the 
inhibitor of apoptosis proteins (IAP). Survivin, identified 
recently, is the most structurally unique member of the IAP 
family and functions in controlling cell division and the 
inhibition of apoptosis. As survivin is expressed in most 
human tumors but rarely in terminally differentiated normal 
tissues, its expression follows a tumor-specific pattern. 
Liang et al. [13] suggested that a DNAzyme targeting sur-
vivin mRNA markedly increases apoptosis and inhibits the 
growth of human pancreatic carcinoma cell lines. The re-
sults also showed that the survivin-targeted DNAzyme can 
block the cells from entering into S phase and passing 
through the G2/M checkpoint. 
It is well known that caspases play an important role in 
apoptosis. Recently, it has been reported that loss of caspase- 
2, one member of the caspases family, can lead to malig-
nancy, suggesting that caspase-2 is a tumor suppressor. 
However, the mechanism of this biological effect is still 
unknown. In one recent study, Dass et al. [24] found that 
Dz13, a DNAzyme that cleaves c-Jun mRNA, induces acti-
vation of the caspase-2 protein rather than up-regulating the 
gene’s activity, which results in cells exhibiting signs of late 
apoptosis. These results also confirmed the off-target effects 
of Dz13 in cancer cells. 
1.3  DNAzymes suppress cell adhesion and invasion 
Local invasion of the host tissue and metastasis are hall-
marks of cancer progression, and understanding cancer cell 
motility is essential for therapeutic targeting of cancer [25]. 
It is already known that integrins play a primary role in the 
motility of cancer cells and that the expression levels of 
numerous integrins can be up-regulated during cancer pro-
gression. Among these integrins, the 1-integrin subfamily 
plays a crucial role in the early stages of angiogenesis and 
in the invasiveness of cancer cell lines. A recent study pro-
vided direct evidence that blocking the synthesis of the 
1-integrin subunit using a specific DNAzyme inhibits the 
adhesion and invasion of carcinoma cell lines [14]. Stec   
et al. [26] further suggested that DNAzymes targeting 1- 
1053 and 3-1243 markedly inhibit expression of 1 and 3 
integrin subunits at the level of mRNA and protein, and 
specifically decrease the cell surface expression of corre-
sponding subunits in endothelial cells. In addition, the ad-
hesion, invasion and metastasis of endothelial cells are all 
significantly blocked by the DNAzymes to 1 and 3 mRNA. 
Cancer cells can metastasize only if they penetrate the 
extracellular matrix (ECM) and the basement membrane. 
Urokinase-type plasminogen activator (uPA) receptor (uPAR) 
has been implicated in signal transduction and biological 
processes such as cancer metastasis, angiogenesis and cell 
migration. When bound to its receptor, uPA has the ability 
to trigger proteolysis cascades that, depending on the physi-
ological environment, participate in the ECM and basement 
membrane degradation, activate latent transforming growth 
factor- (TGF-), release basic fibroblast growth factor 
(FGF) or activate zymogens of matrix metalloproteinases 
(MMPs). It is believed that the tissue degradation following 
plasminogen activation facilitates tissue invasion by cancer 
cells and, thus, contributes to metastasis. de Bock et al. [22] 
indicated that the uPAR-targeted DNAzymes, Dz483 and 
Dz720, cleave uPAR transcripts in vitro with high efficacy 
and specificity at a molar ratio of uPAR to Dz as low as 
1:0.2. The decrease of uPAR expression significantly sup-
presses cell invasion and metastasis. The optimum doses of 
DNAzyme are in the range of 1.6–3.2 g/mL. 
It has been well recognized that growth and metastasis of 
solid tumors require continuous angiogenesis. The VEGF 
sub-family of growth factors contains important signaling 
proteins involved in the activation and inhibition of angio-
genesis. A DNAzyme targeting VEGFR-2, one cognate re-
ceptor of VEGF, is found to cleave its substrate efficiently, 
and thus, inhibit the proliferation of endothelial cells and 
tumor growth in vivo [27]. In addition, Dz13 also significant-
ly inhibits endothelial cell proliferation, migration, chemoin-
vasion and tubule formation, which suppressed the growth 
of solid tumors and angiogenesis [28]. 
1.4  DNAzymes enhance cell radiosensitivity 
It has been established that EBV infection is associated with 
the occurrence and development of nasopharyngeal carcinoma 
(NPC). Latent membrane 1 (LMP1) is an important viral 
protein associated with Epstein-Barr virus that has some 
oncogenic properties during latent infection and may lead to 
NPC. A DNAzyme targeting the LMP1 mRNA, Dz1, signif-
icantly down-regulates the expression of LMP1 through NF- 
B, STAT-3, PI3K/Akt, AP-1 and other signaling molecules. 
As a consequence, Dz1 blocks cell proliferation, invasion 
and metastasis and promotes cell apoptosis [7]. Furthermore, 
animal tests demonstrated that Dz1 blocks the solid tumor’s 
growth by down-regulating the expression level of LMP1 in 
vivo and enhances the radiosensitivity of NPC [8]. 
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1.5  Other applications of DNAzymes associated with 
cancer 
DNA methylation, catalyzed by the enzyme DNA methyl-
transferase (DNMT), typically occurs at CpG sites (cyto-
sine-phosphate-guanine sites) in vertebrates. This pattern of 
methylation has recently become an important topic for 
cancer research. Neoplasia is characterized by “methylation 
imbalance” where genome-wide hypo-methylation is ac-
companied by localized hypermethylation and increased 
expression of DNA methyltransferase [29]. The overall 
methylation state in a cell might also be a precipitating fac-
tor in carcinogenesis as evidence suggests that genome- 
wide hypo-methylation can lead to chromosome instability 
and increase mutation rates. The methylation state of some 
genes can be used as a biomarker for tumorigenesis [30]. 
Recently, based on the identification of DNMT and methyl-
ation-sensitive endonucleases, Li et al. [31] designed a sim-
ple, colorimetric and label-free methylation-responsive 
DNAzyme (MR-DNAzyme) that detects DNMT activity. 
This group demonstrated that this strategy for detecting 
DNMT activity could be used in two ways: as a DNAzyme- 
hairpin hybrid probe and in a methylation-responsive DNA- 
based machine. The MR-DNAzyme could also be used to 
conveniently and efficiently monitor the process of DNA 
methylation catalyzed by DNMT. When compared with the 
traditional method to detect DNA methylation, these 
DNAzyme-based methods have many advantages: they are 
less expensive, easier to synthesize and have a higher sensi-
tivity. 
2  Problems and questions on the applications of 
DNAzymes 
Even though DNAzymes can effectively bind to and cleave 
target mRNA in vitro and in vivo, their biological effects are 
easily influenced by many factors, such as the serum stability 
and the delivery strategy. Studies have shown that certain 
chemical modifications can greatly increase the DNAzymes’ 
stability in serum, enhance their target binding affinity and 
extend their half-life. These modifications include phos-
phorothioate (PS) linkages, 3′-3′ inverted nucleotides at the 
3′ end of the DNAzyme and locked nucleic acids (LNAs). 
However, the introduction of PS linkages may affect cleav-
age efficiency and has been associated with toxicity, im-
munological responsiveness and nonspecific reactions. So 
more innovative chemical modifications are needed to 
strengthen the stability of DNAzymes. A further attempt is 
the introduction of hairpin DNAzymes, which are created by 
the addition of stem-loop hairpins to the end of the substrate- 
binding arms of the DNAzyme. While hairpin DNAzymes 
display resistance to nucleolytic degradation and produce 
better gene intervention, they do not induce nonspecific 
effects or cytotoxicity [2,3,32]. 
As in all nucleic acid-based reagents, delivery is an im-
portant issue. Drug delivery systems (DDSs) can help to 
solve the problems and questions about DNAzymes’ stability, 
biological effects and toxicity. Several seminal studies have 
demonstrated that certain DNAzyme delivery systems can 
efficiently encapsulate DNAzymes and transfect them into 
cells without clear toxicity. The first delivery system used 
microspheres of the co-polymers poly(lactic acid) and poly 
(glycolic acid) (PLGA), which encapsulated the DNAzymes 
inside. PLGA microspheres were able to achieve sustained 
release and accumulation of the DNAzyme. In a second 
delivery system, DNAzymes were incorporated into trans-
ferrin-modified PEGylated polyplexes (Tf-PEG-polyplex) 
and administered intraperitoneally or intravenously. Whole 
body imaging (WBI) revealed that the tumors showed high 
fluorescence and a large concentration of DNAzymes. How-
ever, transferrin (Tf) might aid in targeting DNAzymes to 
blood-rich organs, which may induce side effects in these 
organs. A third delivery system used synthetic macromole-
cules with a branched molecular structure called dendrimers. 
They can bind the DNAzymes better and facilitate DNAzymes 
release. So the displayed transfection efficiency can be 
achieved at lower change ratios of DNAzyme: dendrimer as 
compared to other tranfection reagents above mentioned 
[33]. Finally, nanoparticulate systems could enhance the 
efficacy of tumoricidal DNAzymes with no toxicity and no 
side effects. DNAzymes delivered in this manner signifi-
cantly inhibit tumor growth [34]. These results indicate that 
with more suitable delivery systems, the biological effects 
of DNAzymes would be further increased, and the 
DNAzymes could be applied to new subject areas. 
3  Concluding remarks 
Small-molecule nucleic acid technology is now playing an 
important role for the development of gene-targeted therapy. 
New discoveries about nucleic acid have enhanced our 
knowledge of DNA. DNAzymes, first synthesized experi-
mentally in 1994 by Breaker and Joyce, are single-stranded 
DNA catalysts that can cleave the mRNA of targeted genes 
effectively and specifically. 
Recently, gene targeting has entered a new era with the 
development of potent and effective gene intervention tech-
niques that act on mRNA. In particular, DNAzymes, ribo-
zymes, siRNA and ASO have been used to treat diseases, 
including cancer [5]. Among these methods, DNAzymes 
have potentially broader uses in biology, including detecting 
specific genes and knocking down pathophysiologically 
active genes. 
From their early use as tools for molecular dissection, 
DNAzymes are now moving toward clinical applications 
[35]. Since the activity of DNAzymes was first demon-
strated in vivo in 1999, many preclinical studies using  
animal tumor models have indicated that DNAzymes may 
3408 Xu Z J, et al.   Chin Sci Bull   September (2012) Vol.57 No.26 
have clinical utility as inhibitory agents [36]. Characteristics 
of DNAzymes, such as their enhanced stability and lack of 
side effects, as well as improved delivery vehicles, have 
paved the way for DNAzymes to be studied in clinical trials 
[37]. If clinical tests show safety and tolerability, DNAzymes 
may be approved for a much greater range of applications. 
Moreover, with the development of improved DDSs, the 
biological effects of DNAzymes could be enhanced. Although 
the development of DNAzymes as drugs is still in its infan-
cy, these agents may become economical and practical an-
ti-cancer therapies in the near future. 
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